Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Saurabh (Rob) Aggarwal Clear advanced filters

  • Sales in the biologics sector show modest but healthy growth rates for the fourth consecutive year, with cancer drugs garnering the greatest revenues. As the diabetes epidemic grows and innovation of insulins continues, drug companies in that space are moving up in the ranks.

    • Saurabh (Rob) Aggarwal
    Special Features
    Nature Biotechnology
    Volume: 30, P: 1191-1197

  • As of last month, 41 products have been granted breakthrough therapy designations by the US Food and Drug Administration—drugs against cancer, hepatitis C and monogenetic diseases predominate.

    • Saurabh (Rob) Aggarwal
    Special Features
    Nature Biotechnology
    Volume: 32, P: 323-330

  • Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be until biologics' last hurrah?

    • Saurabh (Rob) Aggarwal
    Special Features
    Nature Biotechnology
    Volume: 32, P: 32-39